全球首个零辐射核药研发生产基地蓄势待发,远大医药创新产品管线夯实核药国际领军地位

全景网
07 May

5月7日,受全球创新脓毒症治疗产品STC3141国内II期临床取得重磅进展利好带动,港股科技创新型医药企业远大医药(0512.HK)股价大涨超13%,盘中涨幅一度超过15%,触及6.90港元,截至收盘的6.79港元,远大医药股价较今年1月底的低点已总计上涨超过70%。当日晚间,公司再度传来捷报,其用于治疗前列腺癌的全球创新放射性核素偶联药物(RDC) TLX591 (177Lu- HuJ591)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10